

# **HSIE Results Daily**

### **Contents**

#### **Results Reviews**

- ONGC: We maintain our REDUCE rating on ONGC, with a target price of INR 220 as we expect slower ramp-up in oil & gas production. Q1FY26 reported EBITDA at INR ~187bn (+0.2% YoY, -1.8% QoQ) and PAT at INR ~80bn (-10.2% YoY, +24.4% QoQ), both above our estimate due to higher-than-expected crude oil realization.
- Apollo Hospitals Enterprise: EBITDA (+20% YoY) was 6% ahead of consensus estimates, led by a 15% YoY sales growth. The hospital business grew 11% YoY (ARPP +9% YoY), HealthCo grew by 19% YoY (offline/online sales up 18%/26% YoY) and AHLL grew 19% YoY. Hospital EBITDA grew 15% YoY (margin at 24.5%; +89 bps) and lower Apollo 24/7 spend (-26% YoY) led to a better margin in HealthCo. APHS expects (1) Existing hospitals: to see 13–14% growth with improving occupancy and ARPP growth; margin at 25% in FY26; to increase international patient share to 7% in FY26 and 10% in FY27. (2) the new units (Pune, Delhi Defence Colony, Kolkata, and Sarjapur) to be operationalized in H2 and will have 100 bps drag (INR 1.5 bn) over the next two years; it expects additional 10% growth from new units. (3) HealthCo: GMV to see 25–30% growth (~INR 32 bn) and EBITDA break-even by Q4FY26, led by growth in e-pharmacy, consultation (OPD/IP), diagnostics, and insurance (from Apr'25); cost controls on Apollo 24/7 spend, and (4) AHLL: strong growth and margin improvement. HealthCo de-merger process on track to be completed by FY27 end. We see growth visibility across -Hospitals: improving occupancy, ARPOB growth, and capacity expansion; HealthCo: steady growth in offline and scale-up in Apollo 24/7; and AHLL: steady growth and margin expansion. Factoring in Q1, we have raised EBITDA by 3/2% for FY26/27E and TP to INR 8,950 (27x Q1FY28E EV/E). BUY stays.
- **Jindal Steel & Power:** We maintain BUY rating on Jindal Steel & Power (JSPL) with an unchanged TP of INR 1,050/share (6.5x its FY27E consolidated EBITDA). During Q1FY26, steel demand in India grew 8% YoY. JSPL, however, reported 9/10% decline YoY/QoQ. Despite lower volumes, consolidated EBITDA rose 6/20% YoY/QoQ as NSR firmed up 5% QoQ, coking coal price continued to fall, and iron ore prices remained stable. JSPL maintained its FY26 volume growth guidance of ~7-13%, implying higher growth in subsequent quarters. We estimate its volume to further accelerate once the ongoing expansions are complete during FY26.
- Samvardhana Motherson International: The presence of plants globally, protects the company from any large direct impact of global tariffs, but does leave it exposed to indirect impacts via customers globally. It highlighted that exports from India to the US amounted to just USD10mn in Q1 (0.3% of consolidated revenues). While other exports into the US are majorly via Mexico, and with them being USMCA compliant. With continuing global demand headwinds and supplier distress, and strong balance sheet of the company, we expect the it to close in on acquisition/s, now that the US tariff scenario is getting less foggy. Additionally, it continues to expand its non-auto business, focusing on aerospace and consumer electronics. We value SAMIL at 20x Jun-27 EPS for a TP of INR 115 and maintain ADD.

HSIE Research Team hdfcsec-research@hdfcsec.com



### **HSIE Results Daily**



• Oil India: Our BUY recommendation on Oil India with a revised target price of INR 485 is premised on oil production growth at 7% CAGR and gas production growth at 17% CAGR over FY25-27E. Q1FY26 standalone EBITDA at INR 16.06bn (-34.9% YoY, -19.0% QoQ) and PAT at INR 8.13bn (-44.5% YoY, -48.9% QoQ) came in line with our estimates. Oil and gas production stood at 1.68mmtoe (+0.2%YoY, +1.8% QoQ).



## **ONGC**

## In-line production; gas realization improves

We maintain our REDUCE rating on ONGC, with a target price of INR 220 as we expect slower ramp-up in oil & gas production. Q1FY26 reported EBITDA at INR ~187bn (+0.2% YoY, -1.8% QoQ) and PAT at INR ~80bn (-10.2% YoY, +24.4% QoQ), both above our estimate due to higher-than-expected crude oil realization.

- Standalone financial performance: EBITDA declined sequentially to INR ~186.5bn (+0.2% YoY, -1.8% QoQ) due to lower crude oil price realization. Operating expenditure stood at INR 55.7bn (+5% YoY, -25.5% QoQ). YoY increase in opex was due to higher LNG consumption at the Dahej Terminal. Depreciation and depletion costs increased to ~INR 65.3bn. (+10.8% YoY, +7.4% QoQ) and exploration cost written off decreased significantly to ~INR 14.7bn (-10.4% YoY, -70.8% QoQ). Interest cost came in at ~INR 11.2bn (-5.2% YoY, -5.8% QoQ).
- Standalone operational performance: Q1 net crude oil realization stood at USD 67.9/bbl (-19.8% YoY, -9.2% QoQ). Gas realization stood at INR 23.6/scm (+11.9% YoY, 1.8% QoQ). Crude oil production was at 4.9mmt (+4.9% YoY, -0.5% QoQ) and gas production was at 4.8bcm (+3.6% YoY, -1.0% QoQ). Total oil sales volume, including JV, was at 4.7mmt (+1.1% YoY, -2.6% QoQ), while gas sales volume was at 3.87bcm (+1.4% YoY, -0.3% QoQ).
- Conference call takeaways: (1) While crude oil price realization reduced, natural gas realization increased on account of higher APM price and increased share of New Well Gas (NWG) in overall sales. Revenue from NWG in Q1FY26 stood at ~INR 17bn. (2) Consolidated oil production stood at 5.24mmt (+0.1% YoY, -0.4% QoQ) and consolidated gas production stood at 4.96bcm (-0.9% YoY, -1.0% QoQ). From the KG basin, ONGC is currently producing 30,000+ bpd of oil and 3mmscmd of gas. KG basin guidance exit FY26 with marginal increase in oil production (30,000+ bpd) and gas production reaching 6-7mmscmd. Opal plant is running at ~90% capacity and recorded positive EBITDA of INR 130mn in Q1FY26. Management believes that petchem prices have begun to bottom out and thus aims to achieve 100% utilization by the end of FY26E. (2) Production guidance for FY26E 19.928mmt and 20.110bcm of oil and gas respectively. For FY27E 21mmt of oil and 21.48bcm of gas. (4) Capex guidance for FY26E- INR 300-350bn. This amount will be invested in E&P as well as renewables business.
- Change in estimates and valuation: We have increased our FY26/27E EPS estimates by 7.9%/3.4% to INR 33.46/33.19, owing to strong performance by HPCL and better-than-expected crude oil realization by ONGC. We value ONGC's standalone business and OVL at 7x Sep-26E EPS at INR 160 and investments at INR 60, leading to a TP of INR 220. The stock is currently trading at 10.7x Sep-26E EPS.

#### Standalone financial summary

YE March	Q1	Q4	QoQ	Q1	YoY	FY23*	FY24*	FY25*	FY26E*	FY27F*
(INR bn)	FY26	FY25	(%)	FY25	(%)	1 120	1 121	1125	1 120L	112/1
Revenues	320.0	349.8	(8.5)	352.7	(9.3)	6,848.3	6,430.4	6,632.6	7,046.3	7,465.1
EBITDA	186.6	190.1	(1.8)	186.2	0.2	857.1	1,086.5	888.6	903.7	913.4
APAT	80.2	64.5	24.4	89.4	(10.2)	392.8	583.1	384.4	420.9	417.5
AEPS (INR)	6.4	5.1	24.4	7.1	(10.2)	31.2	46.4	30.6	33.5	33.2
P/E (x)	320.0	349.8	(8.5)	352.7	(9.3)	7.7	5.2	7.8	7.1	7.2
EV/EBITDA (x)						4.9	3.7	4.4	4.2	4.2
RoE (%)						14.5	18.9	11.0	11.2	10.3

Source: Company, HSIE Research | \*Consolidated

#### REDUCE

CMP (as on 13	INR 239	
<b>Target Price</b>	INR 220	
NIFTY	24,619	
-		
KEY CHANGES	OLD	NEW
Rating	REDUCE	REDUCE
Price Target	INR 205	INR 220
EDC -l	FY26E	FY27E
EPS change	7.9%	3.4%

#### **KEY STOCK DATA**

Bloomberg code	ONGC IN
No. of Shares (mn)	12,580
MCap (INR bn) / (\$ mn)	3,003/34,321
6m avg traded value (INR	mn) 2,982
52 Week high / low	INR 345/205

#### STOCK PERFORMANCE (%)

	3M	6 <b>M</b>	12M
Absolute (%)	(1.0)	1.6	(28.9)
Relative (%)	(0.3)	(4.2)	(31.0)

#### **SHAREHOLDING PATTERN (%)**

	Mar-25	Jun-25
Promoters	58.89	58.89
FIs & Local MFs	18.73	18.88
FPIs	9.19	8.88
Public & Others	13.19	13.35
Pledged Shares	0.00	0.00
Source: BSE		

### Nilesh Ghuge

nilesh.ghuge@hdfcsec.com +91-22-6171-7342

#### **Dhawal Doshi**

dhawal.doshi@hdfcsec.com +91-22-6171-7361

#### **Prasad Vadnere**

prasad.vadnere@hdfcsec.com +91-22-6171-7356



## **Apollo Hospitals Enterprise**

## Hospital growth and Healthco scale-up on track

EBITDA (+20% YoY) was 6% ahead of consensus estimates, led by a 15% YoY sales growth. The hospital business grew 11% YoY (ARPP +9% YoY), HealthCo grew by 19% YoY (offline/online sales up 18%/26% YoY) and AHLL grew 19% YoY. Hospital EBITDA grew 15% YoY (margin at 24.5%; +89 bps) and lower Apollo 24/7 spend (-26% YoY) led to a better margin in HealthCo. APHS expects (1) Existing hospitals: to see 13-14% growth with improving occupancy and ARPP growth; margin at 25% in FY26; to increase international patient share to 7% in FY26 and 10% in FY27. (2) the new units (Pune, Delhi Defence Colony, Kolkata, and Sarjapur) to be operationalized in H2 and will have 100 bps drag (INR 1.5 bn) over the next two years; it expects additional 10% growth from new units. (3) HealthCo: GMV to see 25-30% growth (~INR 32 bn) and EBITDA break-even by Q4FY26, led by growth in e-pharmacy, consultation (OPD/IP), diagnostics, and insurance (from Apr'25); cost controls on Apollo 24/7 spend, and (4) AHLL: strong growth and margin improvement. HealthCo de-merger process on track to be completed by FY27 end. We see growth visibility across - Hospitals: improving occupancy, ARPOB growth, and capacity expansion; HealthCo: steady growth in offline and scale-up in Apollo 24/7; and AHLL: steady growth and margin expansion. Factoring in Q1, we have raised EBITDA by 3/2% for FY26/27E and TP to INR 8,950 (27x Q1FY28E EV/E). BUY stays.

- Q1 highlights: Sales grew 15% YoY to INR 58.42 bn, led by 11% growth in hospitals (ARPP +9%). HealthCo grew 19% and AHLL grew 11%. Steady staff (+8%) and SG&A (+9%; Apollo 24/7 spend at INR 963 mn, -26%) led to an EBITDA of INR 8.52 bn (+26%) and 14.6% margin (+131 bps). PAT was at INR 4.33 bn (+42% YoY). EBITDA: (1) Hospital: +15% YoY, margin at 24.5% (+89 bps). (2) HealthCo: EBITDA at INR 937 mn; Offline: +20% YoY and margin at 7.7% (+16 bps). (3) AHLL: +30% YoY and margin at 9.3% (+82 bps).
- Operating metrics: Hospital: ARPP was at INR 172,382 (+9% YoY) and occupancy at 65% (68% in Q1FY25). IP/OPD volume grew 3/9% YoY. ALOS steady at 3.14 days. Healthco: GMV at INR 6.82 bn (+23% YoY), omnichannel sales grew 21%; added 116 stores (6,742 as of Jun-25).
- Concall takeaways: Sales impact of 1.5% due to reduction in Bangladesh patients; focus to expand in Africa, Middle East, Southeast Asia, and Iraq to offset slower recovery in Bangladesh. Insurance/cash patients grew 15%/16% YoY; surgical grew 14% and CONGO grew 15%. ARPP growth led by increase in tariff (4-5% YoY) and better case mix. Digital Insurance: Started in Apr'25, Q1 GMV was at INR 50 mn; to ramp up in subsequent quarters. Apollo 24/7 spend: improving unit economics which is driven by customer acquisition, delivery, and discounts; to reduce marketing and customer acquisition costs.

**Quarterly financial summary** 

Quarterry 11	indirecto									
(INR mn)	1QFY26	1QFY25	YoY (%)	4QFY25	QoQ (%)	FY24	FY25	FY26E	FY27E	FY28E
Net Revenue	58,421	50,856	15	55,922	4	1,90,592	2,17,940	2,53,763	3,01,432	3,49,247
EBITDA	8,519	6,751	26	7,697	11	23,907	30,219	38,054	46,248	54,972
APAT	4,328	3,052	42	3,896	11	9,054	14,312	19,626	25,333	31,521
EPS (INR)	30.1	21.2	42	27.1	11	63.0	99.5	136.5	176.2	219.2
P/E (x)						124.4	78.7	57.4	44.4	35.7
EV/EBITDA (x)						48.8	39.1	30.8	25.1	20.7
RoCE (%)						15	16	18	20	22

 $Source: Company, HSIE\ Research, PAT\ adjusted\ for\ one-offs.$ 

#### BUY

CMP (as on 1	INR 7,830	
<b>Target Price</b>	INR 8,950	
NIFTY	24,619	
KEY CHANGES	OLD	NEW
Rating	BUY	BUY
Price Target	INR 8650	INR 8950
EPS %	FY26E	FY27E
	2.8	1.7

#### KEY STOCK DATA

Bloomberg code	APHS IN
No. of Shares (mn)	144
MCap (INR bn) / (\$ mn)	1,123/12,834
6m avg traded value (IN	NR mn) 3,032
52 Week high / low	INR 7,840/6,001

#### STOCK PERFORMANCE (%)

	3M	6 <b>M</b>	12M
Absolute (%)	12.9	22.5	18.5
Relative (%)	13.6	16.8	16.5

#### **SHAREHOLDING PATTERN (%)**

	Mar-25	Jun-25
Promoters	29.34	29.34
FIs & Local MFs	22.29	21.34
FPIs	42.74	43.49
Public & Others	5.63	5.83
Pledged Shares	13.5	13.1
Source: BSE		

#### Mehul Sheth

mehul.sheth@hdfcsec.com +91-22-6171-7349

#### Divyaxa Agnihotri

divyaxa.agnihotri@hdfcsec.com +91-22-6171-7362



## Jindal Steel & Power

## Volumes slump; healthy pricing drives margin

We maintain BUY rating on Jindal Steel & Power (JSPL) with an unchanged TP of INR 1,050/share (6.5x its FY27E consolidated EBITDA). During Q1FY26, steel demand in India grew 8% YoY. JSPL, however, reported 9/10% decline YoY/QoQ. Despite lower volumes, consolidated EBITDA rose 6/20% YoY/QoQ as NSR firmed up 5% QoQ, coking coal price continued to fall, and iron ore prices remained stable. JSPL maintained its FY26 volume growth guidance of ~7-13%, implying higher growth in subsequent quarters. We estimate its volume to further accelerate once the ongoing expansions are complete during FY26.

- Q1FY26 performance: India's finished steel consumption rose 8/10% YoY during Q2/H1CY25. However, JSPL's consolidated sales volume fell 9% YoY. Share of VAP increased to 72% vs 64/58% QoQ/YoY on rising focus on value-added sales. Share of flat sales stood at 44% vs 42/43% QoQ/YoY. Blended NSR rose 5% QoQ on account of higher pricing at start of the quarter, benefitting from the safeguard duties and good demand. While iron ore prices were stable, coking coal prices fell by ~USD 11/MT QoQ. These boosted gross margin QoQ. Additionally, there were one-off other expenses in Q4. The gains were partly moderated by op-lev loss (volume down 10% QoQ) and hence unit EBITDA improved by ~INR 4k/MT QoQ to INR 15.8k/MT. Captive coal usage stood at 90-95% during the quarter. JSPL spent INR 22bn in Capex (down 20/4% YoY/QoQ). Net debt increased by ~INR 24bn QoQ on account of similar increase in working capital.
- Concall KTAs and outlook: Despite the volume decline in Q1, JSPL maintained its FY26 sales volume guidance of 8.5-9mn MT (~7-13% YoY growth). Coking coal prices should reduce further by ~USD 5/MT QoQ in Q2 while iron ore prices should remain steady. However, gross margin should feel the heat as steel prices have come off ~5-7% QoQ. Company expects some recovery in steel prices hereon. Company reiterated that its crude steel expansion at Angul (by 6.3mn MT) will be fully commissioned by the end of FY26. This should accelerate volume growth FY27 onwards, in our view. We maintain our volumes and earnings estimates. We build in 11/30% volume growth YoY for FY26/27E, leading to 35/45% EBITDA/APAT CAGR during FY25-27E.

#### Quarterly/annual financial summary (consolidated)

YE Mar	Q1 FY26	Q1 FY25	YoY (%)	Q4 FY25	QoQ (%)	FY23	FY24	FY25	FY26E	FY27E
Sales (mn MT)	1.9	2.1	(9.1)	2.1	(10.8)	7.6	7.7	7.7	8.8	11.5
NSR (INR/MT)	64,708	65,157	(0.7)	61,857	4.6	69,286	65,643	62,897	64,784	65,431
EBITDA(INR/MT)	15,819	13,585	16.4	11,738	34.8	12,936	13,298	11,912	13,724	15,003
Net Sales	122.9	136.2	-9.7	131.8	-6.7	532.1	503.5	501.3	573.1	752.5
EBITDA	30.1	28.4	5.9	25.0	20.1	99.3	102.0	94.9	121.4	172.5
APAT	14.9	13.4	11.5	10.6	40.5	45.6	59.4	40.4	52.6	85.4
AEPS (INR)	147.7	132.5	11.5	105.1	40.5	45.4	59.2	39.9	52.0	84.4
EV/EBITDA (x)						10.1	10.2	10.6	9.0	6.2
P/E (x)						21.1	16.2	23.8	19.1	11.7
RoCE (%) pre-tax						12.4	11.8	9.7	12.0	16.6
RoE (%)						12.0	14.2	8.8	10.5	15.1

Source: Company, HSIE Research

#### BUY

CMP (as on 13	INR 995	
<b>Target Price</b>	INR 1,050	
NIFTY	24,619	
KEY CHANGES	OLD	NEW
Rating	BUY	BUY
Price Target	INR 1050	INR 1050
EBITDA revision %	FY26E -	FY27E

KEV	CT	OCK	D	۸Т	٨

Bloomberg code	JSP IN
No. of Shares (mn)	1,020
MCap (INR bn) / (\$ mn)	1,016/11,618
6m avg traded value (INR	mn) 1,748
52 Week high / low	INR 1,074/723

#### STOCK PERFORMANCE (%)

	3M	6 <b>M</b>	12M
Absolute (%)	9.5	18.5	9.6
Relative (%)	10.3	12.8	7.6

#### **SHAREHOLDING PATTERN (%)**

	Mar-25	Jun-25
Promoters	62.22	62.36
FIs & Local MFs	17.72	18.09
FPIs	9.59	9.76
Public & Others	10.47	9.79
Pledged Shares	7.06	6.95
Source : BSE		

Pledged shares as % of total shares

#### Rajesh Ravi

rajesh.ravi@hdfcsec.com +91-22-6171-7352

#### **Keshav Lahoti**

keshav.lahoti@hdfcsec.com +91-22-6171-7353

#### Riddhi Shah

riddhi.shah@hdfcsec.com +91-22-6171-7359

#### Mahesh Nagda

mahesh.nagda@hdfcsec.com +91-22-6171-7319



## Samvardhana Motherson International

## Transitory costs impact the quarter

The presence of plants globally, protects the company from any large direct impact of global tariffs, but does leave it exposed to indirect impacts via customers globally. It highlighted that exports from India to the US amounted to just USD10mn in Q1 (0.3% of consolidated revenues). While other exports into the US are majorly via Mexico, and with them being USMCA compliant. With continuing global demand headwinds and supplier distress, and strong balance sheet of the company, we expect the it to close in on acquisition/s, now that the US tariff scenario is getting less foggy. Additionally, it continues to expand its non-auto business, focusing on aerospace and consumer electronics. We value SAMIL at 20x Jun-27 EPS for a TP of INR 115 and maintain ADD.

- Quarterly performance: Q1FY26 EBITDA margin at 8.1% was down 148bps YoY and 88bps QoQ, -105bps below our estimate and 79bps below Bloomberg consensus estimate. Revenue growth of 4.7% YoY to INR 302bn was led by 42.9% growth in the emerging business division (forming 10.5% of the revenue mix).
- Call takeaways: (1) Management mentioned that it launched a series of transformative initiatives in Central & Western Europe, for which it has booked an exceptional expense of INR1.35bn in Q1, and the outcome of which will lead to meaningful savings over the next few quarters. (2) It mentioned that a key impact has been coming from the customers recalibrating their powertrain mix which impacts product schedules. (3) It highlighted that the greenfield plants are broadly as per schedule, and should ramp up in H2FY26. (4) Though two greenfield plants, one for aerospace and once for elastomers, have been postponed by a couple of quarters. (5) It indicated that there was no impact on the consumer electronics business from higher US tariffs as it is exempt from those, and the customer has not indicated any change in schedules. (6) On the emerging business, it mentioned that while volumes have been going up, EBITDA will follow as the consumer electronics division ramps up, the Atsumitec acquisition integrates better, and the aerospace division recovers from a seasonally weak Q1. (7) It highlighted that the company has around 30 plants in China, and supplies to Chinese OEMs, and it would benefit if the Chinese OEMs were to also do well globally. (8) It stuck to its capex guidance of INR 60bn (+/- 10%) for FY26, though it could assess it at a later point in time as global business developments continue; while it spent INR 12bn on capex in Q1. (9) It mentioned that higher leverage of 1.1x Net debt/EBITDA was on account of higher working capital in Q1 on the back of supply chain uncertainty and forex volatility.

## Quarterly/annual financial summary

YE Mar (INR mn)	1QFY26	1QFY25	YoY (%)	4QFY25	QoQ (%)	FY25	FY26E	FY27E	FY28E
Net Sales	3,02,120	2,88,680	4.7	2,93,168	3.1	11,36,626	12,55,331	14,02,170	15,62,161
EBITDA	24,583	27,753	(11.4)	26,429	(7.0)	1,05,519	1,19,249	1,43,280	1,66,525
EBITDA Margin %	8.1	9.6	-148 bps	9.0	-88 bps	9.3	9.5	10.2	10.7
APAT	6,147	9,942	(38.2)	10,505	(41.5)	38,030	44,066	57,588	69,852
Diluted EPS (INR)						3.6	4.2	5.5	6.6
P/E (x)						25.9	22.3	17.1	14.1
EV / EBITDA (x)						8.6	7.3	6.0	4.8
RoE (%)						12.5	12.2	14.7	16.2

Source: Company, HSIE Research

### **ADD**

CMP (as on 13	INR 93	
Target Price		INR 115
NIFTY		24,619
KEY CHANGES	OLD	NEW
Rating	ADD	ADD
Price Target	INR 115	INR 115
EDC 0/	FY27E	FY28E
EPS %	0.0	0.0

Note: Company issued a bonus of 1:2 on 21 July 2025. Hence our old adjusted target price became Rs.115 (from Rs.173).

#### **KEY STOCK DATA**

Bloomberg code	MOTHERSO IN
No. of Shares (mn)	10,554
MCap (INR bn) / (\$ mn)	986/11,266
6m avg traded value (INI	R mn) 2,234
52 Week high / low	INR 145/72

#### STOCK PERFORMANCE (%)

	3111	OIVI	12111
Absolute (%)	(1.7)	7.9	(22.5)
Relative (%)	(0.9)	2.1	(24.5)

#### **SHAREHOLDING PATTERN (%)**

	Mar-25	July-25
Promoters	58.1	48.6
FIs & Local MFs	21.0	20.7
FPIs	12.4	12.7
Public & Others	8.5	18.0
Pledged Shares	2.4	2.9

Source: BSE

Pledged shares as % of total shares Note: Sumitomo Wiring Systems, Ltd., Japan and H. K. Wiring Systems, Limited, Hong Kong have been reclassified from 'Promoters' to 'Public & Others'.

#### Hitesh Thakurani

hitesh.thakurani@hdfcsec.com +91-22-6171-7350

#### Shubhangi Kejriwal

shubhangi.kejriwal@hdfcsec.com +91-22-6171-7327



## Oil India

## Decreased realization impacts profitability

Our BUY recommendation on Oil India with a revised target price of INR 485 is premised on oil production growth at 7% CAGR and gas production growth at 17% CAGR over FY25-27E. Q1FY26 standalone EBITDA at INR 16.06bn (-34.9% YoY, -19.0% QoQ) and PAT at INR 8.13bn (-44.5% YoY, -48.9% QoQ) came in line with our estimates. Oil and gas production stood at 1.68mmtoe (+0.2%YoY, +1.8% QoQ).

- Standalone financial performance: EBITDA for Q1FY26 came in at INR 16.1bn (-34.9% YoY, -19.0% QoQ). Other expenses increased to INR 16.9bn(+79.9% YoY, +5.9% QoQ). PAT stood at INR 8.1bn (-44.5% YoY, -48.9% QoQ). Depreciation was at INR 5.3bn (+16.6% YoY, +22.9% QoQ) and interest cost was at INR 1.5bn (-22.1% YoY, -21.4% QoQ).
- Standalone operational performance: In Q1FY26, net crude oil realization stood at USD 64.2/bbl (-22.2% YoY, -11.3% QoQ) and gas realization was at USD 6.7/mmbtu (+4.3% YoY, +3.0 QoQ). Oil production came in at 0.85mmt (-2.1% YoY, +1.1% QoQ). Gas production of 0.80bcm (+2.8% YoY, +2.7% QoQ) was recorded in the quarter. Oil sales volume was at 0.82mmt (-1.4% YoY, -3.1% QoQ), while gas sales volume was at 0.70bcm (+2.8% YoY, +4.5% QoQ).
- Conference call highlights: (1) NRL reported EBITDA of ~INR 7.86 bn and PAT of ~INR 4.88 bn for the quarter. GRM and inventory loss for Q1FY26 stood at USD 5.02/2.93 per bbl respectively. (2) NRL's additional refining capacity to come onstream in H1FY27E. NRL will achieve 40% of the overall refining capacity by H2FY27E. (3) NRL benefited to the tune of INR 1.18bn due to increase in excise duty in Q1FY26. (4) OINL FY26 production guidance 3.7mmtpa of oil and 3.65mmtoe of gas. FY27 production guidance 3.95mmtpa of oil and 4.31mmtoe of gas. (5) FY26/27 capex guidance for standalone entity- INR 69.9/75.8bn. (6) NRL capex guidance for FY26/27- INR 91.3/73bn. (7) USD 17/11.2mn worth of dividend was received in Q1FY26 from Russian assets (Taas-Yuryah Neftegazodobycha and Vankorneft).
- Change in estimates and valuation: We tweak our FY26/27E EPS estimates by +9.9/+5.7% to INR 40.7/41.2, owing to better-than-expected GRM of NRL during the quarter and factoring in higher refining throughput of NRL in FY27E due to expected commissioning of new refinery. We value Oil India's standalone business at INR 220/sh (8x Sep-26E EPS) and its investments at INR 265/sh.

#### Standalone financial summary

YE March (INR bn)	Q1 FY26	Q4 FY25	QoQ (%)	Q1 FY25	YoY (%)	FY23*	FY24*	FY25*	FY26E*	FY27E*
Revenues	50.1	55.1	(9.2)	58.3	(14.2)	410	363	362	351	502
EBITDA	16.1	19.8	(19.0)	24.7	(34.9)	153	125	112	111	121
APAT	8.1	15.9	(48.9)	14.7	(44.5)	87	83	66	66	67
AEPS (INR)	5.0	9.8	(48.9)	9.0	(44.5)	53.7	51.0	40.3	40.7	41.2
P/E (x)						8.0	8.4	10.7	10.6	10.4
EV/EBITDA (x)						5.8	7.4	8.7	6.8	6.1
RoE (%)						25.3	19.1	13.4	12.4	11.0

Source: Company, HSIE Research | \*Consolidated

#### Changes in estimates

YE March		FY26E		FY27E			
i E March	Old	New	(%)	Old	New	(%)	
EBITDA (INR bn)	109	111	1.7	115	120	4.4	
EPS	37.0	40.7	9.9	38.9	41.2	5.7	

Source: HSIE Research

#### BUY

CMP (as on 13	INR 407	
Target Price		INR 485
NIFTY		24,619
KEY CHANGES	OLD	NEW
Rating	BUY	BUY
Price Target	INR 490	INR 485
EDC abongs	FY26E	FY27E
EPS change	+9.9%	+5.7%

#### KEY STOCK DATA

Bloomberg code	OINL IN
No. of Shares (mn)	1,627
MCap (INR bn) / (\$ mn)	662/7,567
6m avg traded value (INR m	n) 1,456
52 Week high / low	INR 768/322

#### STOCK PERFORMANCE (%)

	3M	6M	12M
Absolute (%)	(0.1)	(1.4)	(40.8)
Relative (%)	0.6	(7.2)	(42.8)

#### **SHAREHOLDING PATTERN (%)**

	Mar-25	Jun-25
Promoters	56.66	56.66
FIs & Local MFs	15.97	17.66
FPIs	11.00	9.51
Public & Others	16.38	16.18
Pledged Shares	0.00	0.00
Source : BSE		

## Nilesh Ghuge

nilesh.ghuge@hdfcsec.com +91-22-6171-7342

#### **Dhawal Doshi**

dhawal.doshi@hdfcsec.com +91-22-6171-7361

#### **Prasad Vadnere**

prasad.vadnere@hdfcsec.com +91-22-6171-7356




#### **Rating Criteria**

BUY: >+15% return potential
ADD: +5% to +15% return potential
REDUCE: -10% to +5% return potential
SELL: > 10% Downside return potential

#### **Disclosure:**

Analyst	Company Covered	Qualification	Any holding in the stock
Nilesh Ghuge	ONGC, Oil India	MMS	NO
Dhawal Doshi	ONGC, Oil India	CA	NO
Prasad Vadnere	ONGC, Oil India	MSc	NO
Mehul Sheth	Apollo Hospitals Enterprise	MBA	NO
Divyaxa Agnihotri	Apollo Hospitals Enterprise	MSc	NO
Rajesh Ravi	Jindal Steel & Power	MBA	NO
Keshav Lahoti	Jindal Steel & Power	CA, CFA	NO
Riddhi Shah	Jindal Steel & Power	MBA	NO
Mahesh Nagda	Jindal Steel & Power	CA	NO
Hitesh Thakurani	Samvardhana Motherson International	MBA	NO
Shubhangi Kejriwal	Samvardhana Motherson International	MSc	NO



#### **HSIE Results Daily**



#### Disclosure:

Authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. SEBI conducted the inspection and based on their observations have issued advise/warning. The said observations have been complied with. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

Research Analyst or his/her relative or HDFC Securities Ltd. does not have any financial interest in the subject company. Also Research Analyst or his relative or HDFC Securities Ltd. or its Associate may have beneficial ownership of 1% or more in the subject company at the end of the month immediately preceding the date of publication of the Research Report. Further Research Analyst or his relative or HDFC Securities Ltd. or its associate does have/does not have any material conflict of interest.

HDFC Securities Limited (HSL) is a SEBI Registered Research Analyst having registration no. INH000002475.

#### Disclaimer:

This report has been prepared by HDFC Securities Ltd and is solely for information of the recipient only. The report must not be used as a singular basis of any investment decision. The views herein are of a general nature and do not consider the risk appetite or the particular circumstances of an individual investor; readers are requested to take professional advice before investing. This report may have been refined using AI tools to enhance clarity and readability.

Nothing in this document should be construed as investment advice. Each recipient of this document should make such investigations as they deem necessary to arrive at an independent evaluation of an investment in securities of the companies referred to in this document (including merits and risks) and should consult their own advisors to determine merits and risks of such investment. The information and opinions contained herein have been compiled or arrived at, based upon information obtained in good faith from sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. Descriptions of any company or companies or their securities mentioned herein are not intended to be complete. HSL is not obliged to update this report for such changes. HSL has the right to make changes and modifications at any time.

This report is not directed to, or intended for display, downloading, printing, reproducing or for distribution to or use by, any person or entity who is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject HSL or its affiliates to any registration or licensing requirement within such jurisdiction.

If this report is inadvertently sent or has reached any person in such country, especially, United States of America, the same should be ignored and brought to the attention of the sender. This document may not be reproduced, distributed or published in whole or in part, directly or indirectly, for any purposes or in any manner.

Foreign currencies denominated securities, wherever mentioned, are subject to exchange rate fluctuations, which could have an adverse effect on their value or price, or the income derived from them. In addition, investors in securities such as ADRs, the values of which are influenced by foreign currencies effectively assume currency risk. It should not be considered to be taken as an offer to sell or a solicitation to buy any security.

This document is not, and should not, be construed as an offer or solicitation of an offer, to buy or sell any securities or other financial instruments. This report should not be construed as an invitation or solicitation to do business with HSL. HSL may from time to time solicit from, or perform broking, or other services for, any company mentioned in this mail and/or its attachments.

HSL and its affiliated company(ies), their directors and employees may; (a) from time to time, have a long or short position in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

HSL, its directors, analysts or employees do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any action taken on basis of this report, including but not restricted to, fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc.



HSL and other group companies, its directors, associates, employees may have various positions in any of the stocks, securities and financial instruments dealt in the report, or may make sell or purchase or other deals in these securities from time to time or may deal in other securities of the companies / organizations described in this report. As regards the associates of HSL please refer the website.

HSL or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

HSL or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction in the normal course of business.

HSL or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither HSL nor Research Analysts have any material conflict of interest at the time of publication of this report. Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. HSL may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Research entity has not been engaged in market making activity for the subject company. Research analyst has not served as an officer, director or employee of the subject company. We have not received any compensation/benefits from the subject company or third party in connection with the Research Report.

Please note that HDFC Securities has a proprietary trading desk. This desk maintains an arm's length distance with the Research team and all its activities are segregated from Research activities. The proprietary desk operates independently, potentially leading to investment decisions that may deviate from research views.

HDFC securities Limited, I Think Techno Campus, Building - B, "Alpha", Office Floor 8, Near Kanjurmarg Station, Opp. Crompton Greaves, Kanjurmarg (East), Mumbai 400 042 Phone: (022) 3075 3400 Fax: (022) 2496 5066

Compliance Officer: Murli V Karkera Email: complianceofficer@hdfcsec.com Phone: (022) 3045 3600

For grievance redressal contact Customer Care Team Email: customercare@hdfcsec.com Phone: (022) 3901 9400

HDFC Securities Limited, SEBI Reg. No.: NSE, BSE, MSEI, MCX: INZ000186937; AMFI Reg. No. ARN: 13549; PFRDA Reg. No. POP: 11092018; IRDA Corporate Agent License No.: CA0062; SEBI Research Analyst Reg. No.: INH000002475; SEBI Investment Adviser Reg. No.: INA000011538; CIN - U67120MH2000PLC152193

Investment in securities market are subject to market risks. Read all the related documents carefully before investing. Mutual Funds Investments are subject to market risk. Please read the offer and scheme related documents carefully before investing.

Registration granted by SEBI, membership of BASL (in case of IAs) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

# **HDFC Securities Institutional Equities**

Unit No. 1602, 16th Floor, Tower A, Peninsula Business Park,

Senapati Bapat Marg, Lower Parel, Mumbai - 400 013

Board: +91-22-6171-7330 www.hdfcsec.com